epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-620, Phase III. In planning
Chronic obstructive pulmonary disease with frequent exacerbations
LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.
When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.
Study and plan
Litware Respiratory (fictional), Phase III, Respiratory. Month 0 is January 2027.
Randomise 706 (drop-out 15%) and screen about 1177 (screen failure 40%)
Jul 2029
Confidence wanted
Sites per countryThe fewest sites that finish by the deadline with the confidence above, within each country's cap
How much sites differSpread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
Central finish (P50)Feb 2029month 25.8
Fast case (P10)Nov 2028month 22.3
Slow case (P90)Jul 2029month 31.0
Chance of meeting the deadline86%wanted 85%
Sites20720% likely to recruit nobody
Patients to screen1,177to randomise 706
On course to finish in February 2029, four months before the deadline
EPI-620, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast
Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
Month
Fast case
Central
Slow case
Jan 2027
0
0
0
Apr 2027
0
0
0
Jul 2027
7
3
1
Oct 2027
43
30
19
Jan 2028
134
100
73
Apr 2028
278
212
157
Jul 2028
450
346
257
Oct 2028
630
483
360
Jan 2029
706
622
464
Apr 2029
706
706
567
Jul 2029
706
706
673
Oct 2029
706
706
706
Jan 2030
706
706
706
Apr 2030
706
706
706
Jul 2030
706
706
706
Source: epiClinical Poisson-gamma simulation. All data synthetic.
How likely is it to finish by a given month?
About a four-in-five chance of finishing by July 2029
Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 86 of 100 dots finish in time
Drag the handle or
In time: 86%Median Feb 2029Late: 14%
Source: epiClinical Poisson-gamma simulation
Show data
Chance that recruitment is complete by the end of each month
Month
Chance complete by then
Jan 2027
0%
Apr 2027
0%
Jul 2027
0%
Oct 2027
0%
Jan 2028
0%
Apr 2028
0%
Jul 2028
0%
Oct 2028
3%
Jan 2029
27%
Apr 2029
63%
Jul 2029
86%
Oct 2029
96%
Jan 2030
99%
Apr 2030
100%
Jul 2030
100%
Countries
Use
Country
Patients per site per month
Sites open between
Cap
Sites
Patients by finish
United States
0.163
Therapeutic area: 0.400 Respiratory baseline
Country: ×0.75 United States
Site type: ×0.988 Usual mix in United States
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 4.1 to 10.2
100
18
54
United Kingdom
0.182
Therapeutic area: 0.400 Respiratory baseline
Country: ×0.85 United Kingdom
Site type: ×0.975 Usual mix in United Kingdom
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 4.0 to 10.0
44
44
150
Spain
0.215
Therapeutic area: 0.400 Respiratory baseline
Country: ×1 Spain
Site type: ×0.977 Usual mix in Spain
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 7.6 to 13.6
71
71
230
Poland
0.316
Therapeutic area: 0.400 Respiratory baseline
Country: ×1.4 Poland
Site type: ×1.028 Usual mix in Poland
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 11.1 to 17.1
41
41
150
Turkey
0.212
Therapeutic area: 0.400 Respiratory baseline
Country: ×1 Turkey
Site type: ×0.965 Usual mix in Turkey
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 6.0 to 12.0
18
18
64
India
0.230
Therapeutic area: 0.400 Respiratory baseline
Country: ×1.1 India
Site type: ×0.952 Usual mix in India
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
Competing trials: ×1 A few ×1
month 6.0 to 12.0
15
15
58
Country risks to weigh when choosing sites
United States
Two sourced risks
All sites
The first US site opens quickly, but the rest of the US sites open slowly.
The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B
Tightens: site activation overdue
All sites
Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.
Racial and ethnic under-representation · PB-12 · grade A
United Kingdom
Two sourced risks
Some sites
Costing and contracting were the longest start-up step; the national contract has shortened it.
Fragmented, negotiated costing and contracting · POL-03 · grade A
If it recurs
The regulator's backlog of 2023 was cleared, but could recur.
Regulator assessment backlog · POL-02 · grade A
Spain
Two sourced risks
All sites
Site contracts took 117 days in 2016 and about 90 after national templates.
Fragmented, negotiated costing and contracting · POL-03 · grade A
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
Poland
Two sourced risks
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
All sites
A central ethics committee reviews every study; its effect on timelines is not measured.
Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B
Turkey
Four sourced risks
All sites
Ethics committees fell from 145 to 49 in 2024, cutting review capacity.
Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B
Tightens: site activation overdue
All sites
A fixed pharmaceutical exchange rate has caused repeated medicine shortages.
Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D
Tightens: study drug at the site
All sites
Start-up time has not been measured since CRO data from 2014 and 2015.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
If it recurs
Sites in the south-east lie in the 2023 earthquake zone.
Major earthquake in a site region · SH-11 · grade C
India
Two sourced risks
All sites
Vulnerable participants in trials of new drugs need an audio-visual record of their consent.
Mandatory audio-visual consent for all participants · RW-03 · grade C
Tightens: consent findings
All sites
Start-up time is unmeasured beyond the statutory 90 working days.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
Tightens: site activation overdue
Risk-register entries; the choice of entries per country is epiClinical's.